



Supplementary Figure 8. Treatment naïve chemotaxis between control and pembrolizumab patient PBTs is the same. (A) Y-COM measurements of treatment naïve (TN) activated PBTs from control (CTR; n = 12 patients) and Pembrolizumab (α-PD1; n = 22 patients) patients towards CXCL12 gradient. (B) Y-COM measurements of TN activated PBTs from non-responder (NR; n = 11 patients) and responder (R; n = 11 patients) and post-treatment (PT) activated PBTs from NR (n = 10 patients) and R (n = 11 patients) patients. (A-B) Means are represented by the red bars. Data were compared using student's t-test.